Supernus Announces Second Quarter 2021 Financial Results
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
- Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
- Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinsons disease, cervical dystonia and chronic sialorrhea.
- This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
- These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.